Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Unraveling the Etiology, Therapeutics, and Molecular Signatures of Triple-Negative Breast Cancer"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 14882
Special Issue Editors
Interests: mammary gland development; bone development; molecular immunology; triple negative breast cancer; breast cancer therapeutics; Wnt signaling; cancer health disparities
Interests: nuclear receptors; estrogen biology; bone development; mammary gland development; ER-positive breast Cancer; GATA4; TNBC; osteosarcoma; cancer therapeutics
Interests: breast cancer therapeutics; mammary gland biology; TNBC; HIF1/2 signaling; genetically modified mouse models
Special Issue Information
Triple-negative breast cancer (TNBC, estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), and HER2 not amplified) is an aggressive subtype of breast cancer that frequently occurs in BRCA1 mutation carriers and young women of African descent. TNBC is highly metastatic and carries a poor prognosis. This type of tumor is treated with a combination of therapies, i.e., surgery, radiation therapy, and chemotherapy. Unlike other breast cancer subtypes, there are no FDA-approved targeted agents. The etiology of TNBC is controversial and is very heterogenous with at least four to six subtypes. The immune heterogeneity of TNBC has provided some hope as checkpoint inhibitors work in a minority of TNBCs but not in most subtypes. Moreover, the tumor microenvironment in TNBC patients is not well understood and its role in chemoresistance is not yet clear. Wnt and TGFβ signaling, amongst other signaling pathways, have been associated with metastasis and chemoresistance, providing venues to combine inhibitors for these pathways in combination with FDA-approved therapies to combat chemoresistance and metastasis.
This Special Issue aims to provide a comprehensive overview of the state-of-the-art in, and future perspectives of, “Unraveling the Etiology, Therapeutics, and Molecular Signatures of Triple-Negative Breast Cancer”.
Prof. Dr. Gustavo A. Miranda-Carboni
Dr. Susan A. Krum
Dr. Tiffany N. Seagroves
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- decoding of the etiology of TNBC
- novel therapeutics for metastatic chemoresistant TNBC
- unraveling the tumor microenvironment and the heterogenicity of the immune response of TNBC
- characterization of molecular signaling of TNBC